pharmaphorum6d
Dupixent nears EU approval for COPD, as FDA delays
Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...
ADVFN29d
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
SNY Sanofi Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis Approval based on Phase 3 data showing ...
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) announced Friday that the U.S. FDA approved a label expansion for its ...
pharmaphorum2y
Dupixent nears EU approval for rare skin disease prurigo nodularis
Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...
FiercePharma15d
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...